Phase 1 study of mebendazole therapy for refractory/progressive or recurrent pediatric brain tumors (2025)

Peer-Reviewed Study · Phan P, Stapleton SL, Riggins GJ, Koldobskiy MA, Raabe E, Cohen KJ · June 7, 2025

Phan P et al., 2025-06-07: Two-center phase 1 trial of oral mebendazole monotherapy in 17 children with refractory or progressive brain tumors. It found the drug safe up to 2500 mg/m2/day but mean progression-free survival of only 7.6 weeks.

MBZ is safe and tolerable in treating refractory or progressive pediatric brain tumors, with doses up to 2500 mg/m2/day. There was limited evidence of single-agent efficacy.

n/a

Phan P et al., 2025-06-07: Two-center phase 1 trial of oral mebendazole monotherapy in 17 children with refractory or progressive brain tumors. It found the drug safe up to 2500 mg/m2/day but mean progression-free survival of only 7.6 weeks. Study type: phase 1, 3+3 dose escalation, single arm. N=17. Country: United States (Johns Hopkins and Johns Hopkins All Children's Hospital). Dose: mebendazole 1250, 1875 or 2500 mg/m2/day orally three times daily until toxicity or progression. Funder: Accelerate Brain Cancer Cure supported manufacturing; Cinelli Family Foundation salary support. Conflicts: G.J.R. has a financial interest via intellectual property and a license agreement with Bullfrog AI. Maker: mebendazole manufactured with Accelerate Brain Cancer Cure support. Comparator: none. Results: no dose-limiting toxicities; 121 adverse events, 69 possibly/probably related; mean PFS 7.6 weeks (range 2-24).